162 related articles for article (PubMed ID: 12608543)
1. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.
Zobrist RH; Quan D; Thomas HM; Stanworth S; Sanders SW
Pharm Res; 2003 Jan; 20(1):103-9. PubMed ID: 12608543
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.
Zobrist RH; Schmid B; Feick A; Quan D; Sanders SW
Pharm Res; 2001 Jul; 18(7):1029-34. PubMed ID: 11496941
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
[TBL] [Abstract][Full Text] [Related]
5. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.
Sathyan G; Chancellor MB; Gupta SK
Br J Clin Pharmacol; 2001 Oct; 52(4):409-17. PubMed ID: 11678784
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
[TBL] [Abstract][Full Text] [Related]
7. Transdermal drug delivery treatment for overactive bladder.
Dmochowski RR; Starkman JS; Davila GW
Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Gupta SK; Sathyan G
J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.
Mizushima H; Takanaka K; Abe K; Fukazawa I; Ishizuka H
Xenobiotica; 2007 Jan; 37(1):59-73. PubMed ID: 17178634
[TBL] [Abstract][Full Text] [Related]
10. The effects of external heating on the permeation of oxybutynin through human epidermal membrane.
Mizushima H; Inoue K; Ishizuka H
Biol Pharm Bull; 2007 Mar; 30(3):612-5. PubMed ID: 17329869
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
Dmochowski RR; Sand PK; Zinner NR; Gittelman MC; Davila GW; Sanders SW;
Urology; 2003 Aug; 62(2):237-42. PubMed ID: 12893326
[TBL] [Abstract][Full Text] [Related]
12. Oxybutynin topical and transdermal formulations: an update.
Staskin DR; Salvatore S
Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
[TBL] [Abstract][Full Text] [Related]
13. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.
Preik M; Albrecht D; O'Connell M; Hampel C; Anderson R
BJU Int; 2004 Oct; 94(6):821-7. PubMed ID: 15476516
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation.
Sathyan G; Hu W; Gupta SK
J Clin Pharmacol; 2001 Feb; 41(2):187-92. PubMed ID: 11210400
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Reiz JL; Salem P; Darke AC
J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
17. Transdermal oxybutynin: for overactive bladder.
Bang LM; Easthope SE; Perry CM
Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
[TBL] [Abstract][Full Text] [Related]
19. Management of overactive bladder with transdermal oxybutynin.
Starkman JS; Dmochowski RR
Rev Urol; 2006; 8(3):93-103. PubMed ID: 17043706
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on the bioavailability of oxybutynin from a controlled release tablet.
Lukkari E; Castrèn-Kortekangas P; Juhakoski A; Löyttyniemi E; Aranko K; Neuvonen PJ
Eur J Clin Pharmacol; 1996; 50(3):221-3. PubMed ID: 8737763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
